CS
FSTX

Credit Suisse’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Credit Suisse’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,557
Closed -$37K – 4308
2019
Q2 		$37K Buy
+2,557
New +$68.5K ﹤0.01% 4019

Other funds holding FSTX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

Credit Suisse's FSTX Position: Q3 2019 in Review

Credit Suisse sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q3 2019, closing a stake of 2,557 shares — an estimated $37K sold.

Credit Suisse first reported a position in FSTX in Q2 2019 and held it in 1 quarter. The position peaked at $37K in Q2 2019. 40 funds tracked by Wall St. Rank hold FSTX as of Q3 2019.

  • Credit Suisse reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Credit Suisse sold 2,557 F-star Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $37K.
  • Credit Suisse first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Credit Suisse's F-star Therapeutics, Inc. Common Stock position peaked at $37K in Q2 2019.
  • 40 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Credit Suisse's 13F filing for Q3 2019, filed 12 Nov 2019.